Jordan Schecter

Vice President, Clinical Development Cellular Therapy Program • Janssen

Jordan M Schecter, MD is currently the Vice President for Cellular Therapy at Janssen (the Pharmaceutical  Company of Johnson & Johnson). In this role, he is the global clinical leader for Ciltacabtagene Autoleucel (an experimental CAR-T therapy being developed for Multiple Myeloma). Previous to this role, Dr Schecter was the co-Clinical lead for Daratumumab (Darzalex ®), a monoclonal antibody first approved in 2015 for the treatment of multiple myeloma. Prior to joining Janssen, Dr Schecter was an associate professor of medicine at Columbia University Medical Center in New York City where he was involved in clinical research for multiple myeloma and Amyloidosis. He earned his MD at Warren Alpert Medical School and completed his internship at Rhode Island Hospital, both at Brown University and completed his residency and a fellowship in medical haematology and oncology at Columbia University Medical Center.

Also speaking

Frank Luppino

President & Chief Executive Officer • Remedium Bio

Paula Pulsoni

Vice President, Sales and Services • World Courier

Rui A. Sousa

Chief Executive Officer & Chairman • Stemmatters

Event Info


2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.

Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.